Since September, Eli Lilly has launched three significant AI-driven programs designed to accelerate its R&D pipeline and strengthen its competitive moat. In September, it unveiled TuneLab, an AI drug-discovery platform offered at no cost to smaller biotech firms; in exchange for access to Lilly’s algorithms, these partners supply anonymized datasets that bolster Lilly’s own model training. In October, the company formalized a strategic partnership with Nvidia to construct what it terms the most powerful AI supercomputer dedicated to pharmaceutical research, capable of running trillions of calculations per second. Earlier this month, Lilly and Nvidia broke ground on a joint AI drug discovery laboratory in the San Francisco Bay Area, co-locating Lilly’s medicinal chemists with Nvidia’s AI engineers to compress typical discovery timelines by an estimated 30–40%.

In its most recent 13F filings, several large institutions adjusted their positions in Eli Lilly. First Citizens Bank & Trust Co. increased its stake by 58.8%, purchasing 9,121 additional shares to reach a total holding of 24,634 shares valued at $18.8 million as of September 30. By contrast, Commerzbank Aktiengesellschaft trimmed its position by 1.8%, selling 741 shares and ending the quarter with 39,787 shares worth approximately $30.4 million. Overall institutional ownership stands at 82.5%, underscoring both strong faith among major asset managers and ongoing portfolio rebalancing as pension funds and sovereign wealth vehicles fine-tune exposure to the healthcare sector.

Eli Lilly’s oral GLP-1 agent, orforglipron, encountered a regulatory setback when the FDA extended its review window from the originally anticipated late-February decision to an April 10 target date. This extra 1–2 month period follows the award of a priority review voucher in December and gives competitor Novo Nordisk, which launched its own oral GLP-1 last month, additional runway to capture early adopters. Despite this, orforglipron demonstrated phase 3 weight-loss efficacy comparable to injectable alternatives and outperformed in diabetes subpopulations. Given that Lilly’s injectable Zepbound surpassed Novo Nordisk’s subcutaneous injectable in third-quarter sales of 2025, analysts believe the temporary timing disadvantage will not materially erode Lilly’s long-term leadership in the rapidly expanding anti-obesity market.